Advancing brain immunotherapy through functional nanomaterials
Drug Delivery and Translational Research · 2026
DOI: 10.1007/s13346-024-01778-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Delivery and Translational Research, 2026. Verfasst von Bhanu Nirosha Yalamandala und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, 300044, Hsinchu, Taiwan. Hauptthemen laut MEDLINE: Brain Neoplasms, Immunotherapy, Glioblastoma, Nanostructures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taiwan, National Tsing Hua University, National Health Research Institutes.
Abstract (Originalsprache)
Glioblastoma (GBM), a highly aggressive brain tumor, poses significant treatment challenges due to its highly immunosuppressive microenvironment and the brain immune privilege. Immunotherapy activating the immune system and T lymphocyte infiltration holds great promise against GBM. However, the brain’s low immunogenicity and the difficulty of crossing the blood-brain barrier (BBB) hinder therapeutic efficacy. Recent advancements in immune-actuated particles for targeted drug delivery have shown the potential to overcome these obstacles. These particles interact with the BBB by rapidly and reversibly disrupting its structure, thereby significantly enhancing targeting and penetrating delivery. The BBB targeting also minimizes potential long-term damage. At GBM, the particles demonstrated effective chemotherapy, chemodynamic therapy, photothermal therapy (PTT), photodynamic therapy (PDT), radiotherapy, or magnetotherapy, facilitating tumor disruption and promoting antigen release. Additionally, components of the delivery system retained autologous tumor-associated antigens and presented them to dendritic cells (DCs), ensuring prolonged immune activation. This review explores the immunosuppressive mechanisms of GBM, existing therapeutic strategies, and the role of nanomaterials in enhancing immunotherapy. We also discuss innovative particle-based approaches designed to traverse the BBB by mimicking innate immune functions to improve treatment outcomes for brain tumors. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, 300044, Hsinchu, Taiwan.
- Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, 300044, Hsinchu, Taiwan. shhu@mx.nthu.edu.tw.
Förderung
- National Science and Technology Council, Taiwan
- National Tsing Hua University
- National Health Research Institutes
Zitieren
APA
Yalamandala, B. N., Huynh, T. M. H., Lien, H. W., Pan, W. C., Iao, H. M., Moorthy, T., Chang, Y. H., & Hu, S. H. (2026). Advancing brain immunotherapy through functional nanomaterials. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01778-5
Vancouver
Yalamandala BN, Huynh TMH, Lien HW, Pan WC, Iao HM, Moorthy T, et al. Advancing brain immunotherapy through functional nanomaterials. Drug Delivery and Translational Research. 2026. doi:10.1007/s13346-024-01778-5
BibTeX
@article{Yalamandala2026,
author = {Yalamandala, Bhanu Nirosha and Huynh, Thi My Hue and Lien, Hui-Wen and Pan, Wan-Chi and Iao, Hoi Man and Moorthy, Thrinayan and Chang, Yun-Hsuan and Hu, Shang-Hsiu},
title = {Advancing brain immunotherapy through functional nanomaterials},
journal = {Drug Delivery and Translational Research},
year = {2026},
doi = {10.1007/s13346-024-01778-5}
}
EUVIMED